Biogen raises 2017 forecast on Spinraza success

(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy.